Home > Result Summaries: Compounds > ondansetron > Result Summary for S3A40128

Result Summary for S3A40128

Result Summary

Protocol ID:	S3A40128
Clinical Study ID:	S3AM01
Official Title:	A Randomised, Double-blind Study to Compare the Efficacy and Safety of Ondansetron (GR38032) Administered as Either a Single IV Dose or a Continuous Infusion Over 24 hours In Acute Cisplatin-induced Emesis
Phase:	Phase 3
Study Indications or Diseases:	Nausea and Vomiting, Chemotherapy-Induced
Generic Name:	ondansetron
Trade/Product Name:	zofran;zofran
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. a multicentre, double-blind, randomised, parallel group study. ondansetron study group. Seynaeve, C., Schuller, J., Buser, K., Porteder, H., Van Belle, S., Sevelda, P., Christmann, D., Schmidt, M., Kitchener, H., Paes, D., and et, a. l. Br J Cancer 92; 66. (1):192-7